print small

Participating Countries:

Algeria

Argentina

Australia

Austria

Belgium

Bosnia and Herzegovina

Bulgaria

Croatia

Czech Republic

Denmark

Finland

France

FYR of Macedonia

Germany

Greece

Iceland

Ireland

Israel

Italy

Lithuania

Morocco

Netherlands

New Zealand

Poland

Portugal

Romania

Russian Federation

Serbia

Slovenia

Spain

Sweden

Switzerland

Turkey

Ukraine

United Kingdom

United States

Member area provided by LTFE
COST is supported by the EU Framework Programme Horizon 2020
This website is supported by COST
20/11/2013 (Added to site)
Author(s): Matthiessen, L. W.; Johannesen, H. H.; Hendel, H. W.; Moss, T.; Kamby, C.; Gehl, J.

Electrochemotherapy for large cutaneous recurrence of breast cancer: A phase II clinical trial

Journal: Acta Oncologica, 51/6 (2012), pp. 713-721
DOI: 10.3109/0284186X.2012.685524
Tell your friend  | 

Abstract:

Background. Cutaneous recurrences of breast cancer may cause considerable discomfort due to ulceration, oozing, and pain and can also be diffi cult to treat. Electrochemotherapy is a localised anticancer treatment using electric pulses to make cell membranes permeable, augmenting uptake of chemotherapeutic drugs, and thus enabling highly effi cient tumour cell kill. This is the fi rst systematic investigation of electrochemotherapy for larger cutaneous recurrences of breast cancer.

Patients and methods. We conducted a phase II trial for patients with cutaneous recurrences where no further treatment options were available. Primary endpoint was objective response evaluated by clinical examination. Secondary endpoints included response evaluated by PET/CT, change in lung diffusion capacity, patient reported symptoms, and distress related to bodily appearance. Treatment consisted of bleomycin injection followed by application of electric pulses.

Results. Seventeen heavily pre-treated patients received electrochemotherapy. Twelve patients were evaluable (follow-up  8 weeks). CT showed four (33%) patients achieving over 50% tumour volume reduction, clinical examination showed one CR and one PR (OR 17%). Symptomatic relief included decreasing exudates, odour, and bleeding. Treatment was well tolerated; the main side effect was post-treatment pain.

Conclusion. This first phase II study indicates that electrochemotherapy is a promising treatment alternative for cutaneous recurrences of breast cancer.



Project Office

Working groups

Steering Committee

Founding members

DC Rapporteurs

Related sites: